As ADME toxicity studies and drug discovery projects worldwide call for the use of more advanced GPCR assays, platforms, and systems, the demand for G-protein coupled receptors (GPCRs) is expected to be on the growth path. A latest report by Transparency Market Research states that the global GPCRs market will rise in value to reach US$3.53 bn by 2022, up from its 2013 valuation of US$1.63 bn. This translates to an 8.8% CAGR between 2014 and 2022.The report is titled, “G-Protein Coupled Receptors (GPCRs) Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022.
The GPCRs market is composed of various types of kits and assays that aid the process of drug discovery and development. G-protein coupled receptors refer to a group of surface receptors that respond to different kinds of external stimuli. This cell-communication ability makes them useful in a variety of pharmacology processes. A significant factor to consider when understanding what drives the global GPCRs market is that over 30% of the drugs available on the market today target GPCRs. Besides this, a vast number of drugs currently at the clinical or preclinical stage target GPCRs.
Download free exclusive Brochure of this report:
The report segments the global GPCRs market on the basis of assay type, therapeutic areas, and by geography. By assay type, the market has been segmented into: calcium level detection assays, cGMP assays, GTPγS binding assays, receptor internalization assays, reporter gene assays, and cAMP Assays. The largest segment among these is the cAMP assays segment, which accounted for 32.5% of the market in 2013. The segment, however, will not be the fastest growing segment through the report’s forecast period but will exhibit the second-fastest rate of growth.
Considerable promise will also be shown by the reporter gene assays segment, which is predicted to log a considerably high CAGR through the report’s forecast period. An upswing in the demand for technologically advanced and accurate assays and systems will be responsible for the robust growth of the gene assays segment.
Basis therapeutic areas, the report segments the market into: Central nervous system (CNS), cardiovascular system, immune system, oncology, respiratory system, reproductive system, and others. Among these segments, oncology represented the largest segment by revenue and will remain the dominant segment over the report’s forecast period. The attractiveness of oncology therapies for companies in the GPCRs market can be credited to the high prevalence of cancer globally. In 2013, the central nervous system (CNS) segment followed oncology in terms of revenue. The cardiovascular segment stood third globally. Other GPCR therapeutic segments such as immune system, respiratory, and reproductive are projected to exhibit strong growth through the report’s forecast period.
The report also studies the global GPCRs market On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World. According to the TMR report, the global G-protein coupled receptors market was led by North America in 2013 because of the heightened awareness that prevails about the use of advanced assays and the relative affluence of consumers, which enables them to afford high-end treatments. This regional market will report high growth till 2022 owing chiefly to the rise in geriatric patients and people suffering from obesity.
Leading players profiled in the global GPCR market in the report are: Thermo Fisher Scientific, Inc.; Becton, Dickinson and Company; EMD (Merck) Millipore; Cisbio Bioassays; PerkinElmer, Inc.; DiscoveRx Corporation; Qiagen N.V.; Promega Corporation; and HD Biosciences Co. Ltd.